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Abstract
Typical language development requires typical hearing. With sensorineural 
hearing loss (SNHL), the damaged hair cells of the organ of Corti within the 
cochlea interfere with typical hearing and, as a result, cause impaired language 
development. Untreated SNHL causes significant neurocognitive differences in 
affected children. SNHL is a permanent sensory disorder affecting more than 
270 million people worldwide. Congenital SNHL is found in 4 of 1000 newborns. 
Approximately half of congenital SNHL is hereditary and is the result of genetic 
mutations causing improper development of cochlear hair cells. Non-genetic con-
genital SNHL is thought to be the result of an injury to the cochlea typically from 
premature birth, infection, or exposure to ototoxic medications or noise. In mam-
mals, the cochlea is postmitotic at birth, and no spontaneous repair occurs there-
after. Existing treatments for SNHL (hearing aids and cochlear implants) function 
by augmenting the damaged organ of Corti. No reparative treatments currently 
exist. In preclinical and clinical studies, progenitor cell therapy (cord blood and 
mesenchymal stem cells) has shown promise in reversing the underlying pathology 
of SNHL, the loss of cochlear sensory hair cells. Progenitor cell therapy may also 
allow functional reorganization of the auditory pathways including primary audi-
tory cortex (Heschl’s gyrus). We will present a summary of the effect of hearing loss 
on auditory development, existing preclinical and clinical data on progenitor cell 
therapy, and its potential role in the (re)habilitation of non-genetic SNHL.
Keywords: sensorineural hearing loss, human umbilical cord blood, stem cell, 
progenitor cell therapy, cochlea, auditory verbal therapy
1. Introduction
Affecting more than 270 million people worldwide, sensorineural hearing loss 
(SNHL) is a permanent sensory disorder which interferes with hearing. SNHL is 
found in 4/1000 in newborns, 8/1000 children aged 3–17 years, and 33% of adults 
aged 65–74 years [1–3]. Existing treatments (hearing aids and cochlear implants) 
improve the symptoms of SNHL by augmenting the damaged organ of Corti. These 
treatments do not reverse the underlying pathology of SNHL nor loss of sensory inner 
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hair cells within the organ of Corti. Inner and outer cochlear hair cells are necessary 
for hearing and transforming sound waves into electrical impulses transmitted to the 
brain. Loss of hair cells reduces auditory input to the brain, and with sufficient hair 
cell loss, hearing impairment develops. In mammals, the organ of Corti is postmitotic 
at birth, and no spontaneous hair cell regeneration occurs thereafter.
Among infants and children with SNHL, 23–50% is the result of a genetic 
mutation that adversely affects development of the organ of Corti (connexin 26, 
mutation, Waardenburg syndrome, Usher syndrome, Mitochondrial Disorders, 
etc.) [2–9]. The remaining infants and children have acquired SNHL, which is most 
commonly attributed to prematurity, infection (in utero or postdelivery), and 
exposure to noise or ototoxic drugs.
In preclinical and clinical studies, the intravascular delivery of mesenchymal 
progenitor cells following acute neuro-pathologic insults (stroke, traumatic brain 
injury, spinal cord injury, etc.) has shown significant promise [10–16]. Limited 
animal and human data suggest that repair of the mammalian cochlea is possible 
following progenitor cell therapy [3, 17–20]. If these early results can be translated 
to a reparative treatment for SNHL, it would be a transformative advance in audi-
tory (re)habilitation.
1.1 Hearing loss and auditory development
Spoken language is learned and its development is dependent upon both the 
innate ability found within the human cortex as well as environmental stimulation. 
The time frame over which the cortex is capable of learning a fist spoken language 
is finite due to neuroplasticity [21]. Neuroplasticity refers to changes in neural 
connections, pathways, and networks as a result of maturation and development, 
sensory deprivation, injury, disease, dysfunction, and learning [22]. Although 
neuroplasticity exists to some degree throughout life, it is particularly robust during 
early life when neuronal groups are most capable of adjusting function based upon 
input. This window of heightened learning, known as the critical period, lasts 
roughly through 3 years 6 months of age. The critical period is a time when the 
brain effortlessly rewires in response to the environment, and at the end of which 
there is a decisive diminishing of neuroplasticity.
Auditory development is particularly sensitive to the critical period. Auditory 
learning begins in utero [23] when synapses are formed and then strengthened 
at a remarkable rate [24]. At ~4 years of age, the abundant neurons within the 
auditory cortex undergo a rapid pruning phase, during which neurons and their 
synapses are eliminated when unused, and thus considered unnecessary [25, 26]. 
This pruning fundamentally alters the auditory cortex, which for the typically 
hearing child, equals improved language efficiency. Conversely, for the unampli-
fied child with SNHL, pruning results in an inability to develop spoken language. 
It has been observed that if auditory stimulation is not delivered during the early 
optimal period of cortical plasticity, deficits are observed even after the child is 
amplified [27, 28]. A biomarker for auditory cortical maturation is the latency rates 
of the P1 component of the cortical auditory evoked potentials (CAEP). It has been 
demonstrated that the P1 component of the CAEP shows age-related decreases in 
latency, meaning faster transmission, in children without hearing loss. In a series 
of 245 children with congenital deafness, Sharma and Dorman found that the 
latency of the P1 CAEP decreases to within normal limits in children who receive 
a cochlear implant by 3.5 years of age. Children implanted after the age of 7 years 
demonstrate abnormal P1 CAEP responses which persisted even after years of 
experience with implant use. Children implanted between 3.5 and 7 years showed 
mixed auditory cortical development, with some children demonstrating normal P1 
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CAEP responses and others never reaching normal central auditory maturational 
status [28]. Supporting this finding are studies describing developmental outcomes 
of speech and language skills in children implanted at various ages, which indicate 
significantly improved outcomes with younger implantation age [29–31]. Improved 
outcomes are especially true in the development of oral spoken language [32].
In summary, when a child with SNHL is provided auditory access through hear-
ing aids or a cochlear implant in a timely manner within the critical period, auditory 
development, and language acquisition may occur normally. Conversely, children 
who experience long periods of auditory deprivation are susceptible to large-scale 
reorganization of the auditory cortex areas responsible for the perception of speech 
and language [33]. When that reorganization happens, there is evidence that 
several areas of auditory cortex are recruited for visual and tactile input under the 
condition of auditory deprivation [34–37]. To date, the only task specific reorga-
nization of the auditory cortex that has been proven is in deafened cats. Meredith 
and Lomber demonstrated that distinct auditory regions in cats with SNHL sup-
port peripheral visual localization and visual motion detection, and that the same 
regions support auditory localization in hearing cats [38].
1.2 Preclinical evidence for stem cell efficacy in the treatment of SNHL
Animal studies using mesenchymal progenitor cells have provided intriguing 
results in experimentally deafened animals. Using NOD-SCID mice experimentally 
deafened with kanamycin and noise, Revoltella et al. reported recovery of auditory 
function following intravenous treatment with CD-133+ cells derived from human 
umbilical cord blood. Some of the cord blood stem cells were shown to have reached 
the cochlea [17]. In a subsequent study from the same group, Bettini et al. treated 
NOD-SCID mice deafened with kanamycin with mesenchymal stem cells derived 
from either bone marrow or adipose tissue. Both cell types engrafted in the cochlea 
of damaged mice, inducing regeneration of the damaged sensory structures. Several 
hybrid human-mouse fusion cells were found within the cochlea but not in hair 
cells. The data suggest that human MSCs do not directly replace lost cells, but exert 
their regenerative potential mainly through paracrine effects [17, 18, 39].
Using an SNHL guinea pig model, Choi et al. demonstrated both physiological 
and anatomic improvement in the cochlea of animals treated with mesenchymal 
stem cells derived from human umbilical cord blood. Distortion-product otoacous-
tic emissions (DPOAEs) were decreased and auditory brainstem response (ABR) 
thresholds were improved by 40–50 decibels (dB) in treated guinea pigs. In addi-
tion, treated animals demonstrated an increase in both hair cells and spiral ganglion 
cells compared to control animals [19].
1.3 Clinical evidence for stem cell efficacy in the treatment of SNHL
DaCosta et al. reported the effect of cord blood transplantation on SNHL 
following myeloablation in patients with mucopolysaccharidosis [20]. The muco-
polysaccharidoses (MPS) are a group of lysosomal storage diseases in which there is 
a deficiency in one of the enzymes responsible for the breakdown of glycosoamino-
glycosides (GAGs). The progressive buildup of GAGs in cells causes tissue and organ 
injuries. Most patients with MPS present with a mixed hearing loss. As MPS pro-
gresses, GAGs accumulate in the tissues of the nasopharynx ultimately interfering 
with Eustachian tube function and causing chronic otitis media. MPS types 1 and 
2 commonly also develop SNHL. The exact etiology of the MPS associated SNHL is 
not clear but may be a genetic congenital SNHL vs. an acquired injury secondary to 
the accumulation of GAGs in the cochlea or cochlear nerve [40].
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The only treatment that demonstrates long-term metabolic correction and 
neurocognitive improvement in MPS is hematopoietic stem cell transplantation [41, 
42]. In DaCosta’s series, 26 of 30 patients had MPS 1 and 2. Following bone marrow 
transplantation, the ABR click threshold improved by 19 dB on average and 20 of 30 
patients experienced an improvement in sensorineural hearing. The effect on SNHL 
was more prominent in children who underwent bone marrow transplantation at 
less than 25 months of age. The cord blood used for transplantation was allogenic 
and did not carry any of the MPS mutations [20].
1.4 Phase 1 trial: umbilical cord blood therapy for acquired SNHL in children
In a Phase 1 trial, 11 children less than 6 years of age, with severe to profound 
non-genetic SNHL were treated with their own umbilical cord blood mononuclear 
fraction intravenously. Subjects were recruited from a single private cord blood 
bank, cord blood registry, through the bank’s patient email portal. Patients were 
evaluated before treatment and 1-, 6-, and 12-months posttreatment. Evaluations 
included physical and neurological examinations, speech language pathology test-
ing, audiology evaluations, 3-Tesla MRI with diffusion tensor imaging (DTI), and 
laboratory testing.
No significant adverse events occurred during the study. Ten subjects expe-
rienced an expected improvement of speech language pathology test scores over 
the course of the trial. The only subject who failed to improve did not follow study 
mandated amplification and recommended auditory verbal speech language ther-
apy, demonstrating the importance of speech language therapy in this vulnerable 
population. About 5 of the 11 treated subjects experienced an improvement in ABR 
thresholds which achieved statistical significance across the treatment population 
at three measured frequencies. The improvement in ABR threshold ranged from 15 
to 20 dB (Figure 1). There was a trend toward improvement in the latency of signal 
transmission along cranial nerve VIII (Vestibulo-cochlear nerve). Improvements in 
both ABR thresholds and CN VIII latency were evident at 1-month follow-up testing 
and were durable throughout the 12-month study period. The rapid and durable 
change in latency was unexpected.
Using 3 T MRI data collected before and 12-months after cord blood treat-
ment, subjects whose ABR thresholds had improved following were compared 
to subjects whose ABR thresholds had not changed following treatment 
(Figure 2). The DTI measure fractional anisotropy (FA), a marker of white 
matter tract integrity and myelination [43], trended toward improvement 
along the auditory pathways in responding subjects. The changes in FA were 
most prominent in the white matter of Heschl’s gyrus, which is the primary 
auditory cortex (Figure 3).
All responding subjects received a cord blood cell dose of at least 15 million cells 
per kilogram [3].
This trial supports the concept that autologous intravenous cord blood therapy 
can facilitate repair of the cochlea. The data also suggest that improvement in the 
entire auditory pathway might occur following the progenitor cell therapy.
1.5 Possible mechanisms of action
While limited, the existing data suggest that progenitor cell therapy does not 
result in direct replacement of cochlear hair cells, but enables an intrinsic repair 
machinery to work. The immunomodulatory effect of MSCs acting systemically 
and the local effect of MSCs which reach and interact with the cochlear stroma and 
possibly cochlear stem cells may facilitate hair cell replacement. A similar process 
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involving MSCs which cross the blood brain and blood labrynthine barriers and 
interact directly with brain tissue may facilitate repair and reorganization of the 
white matter tracts of the auditory pathway.
While some infused mesenchymal progenitor cells do cross the blood brain bar-
rier and reach the cochlea [17, 18], the majority fail to do so. Because mesenchymal 
stem cells have cell diameters larger than most terminal arterioles, most infused 
MSCs are found within the capillaries of the lungs within minutes of infusion 
Figure 1. 
Representative audiograms (top) and ABR recordings at 4000 Hz (below) of a responding subject before (left) 
and after (right) hUCB treatment for SNHL. The improvements on the behavioral testing (audiogram) match 
the changes found on the ABR recordings (physiologic).
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[44–46]. In both humans and animals, this rapid pulmonary entrapment is followed 
by clearance from the lungs and accumulation in the liver and spleen over subse-
quent hours to days [43–45]. The MSCs, while entrapped, cause a marked change in 
circulating cytokines and immune system phenotype [47]. Notably, human MSCs 
have been shown to be capable of migrating to an area of injury and recruiting 
tissue specific progenitor cells and regulating the immune response through the 
secretion of immunomodulatory cytokines and microvesicles (exosomes) contain-
ing a variety of bioactive molecules including enzymes, coding and non-coding 
RNAs, and growth factors [48]. MSCs are also known to secrete molecules that 
modulate both innate and adaptive immune responses [49]. These secreted mol-
ecules act to inhibit the maturation of monocytes into antigen presenting dendritic 
cells [50], promote a shift in macrophage phenotype from M1 to M2 [51], inhibit the 
Figure 2. 
Raw axial DTI image with the ROI of the right sided Heschl’s gyrus used for FA analysis, outlined in red.
Figure 3. 
Graphical representation of mean fractional anisotropy between responding (blue) and non-responding 
(orange) subjects at region of interest sites in Heschl’s gyrus following cord blood mononuclear treatment for 
SHNL in children. The data suggest an increase in fractional anisotropy in responding subjects, but not in non-
responders. An increase in the fractional anisotropy suggests improved white matter tract integrity and possibly 
the repair of primary auditory cortex.
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proliferation and activation of B and T lymphocytes [52], and promote the clonal 
expansion of regulatory T lymphocytes [53]. This extensive systemic alteration of 
the immune system may facilitate repair through a systemic paracrine effect.
Likewise, the previously identified fusion of MSCs with cochlear support cells 
may also allow cochlear support or cochlear stem cells to differentiate into hair 
cells [18]. Epigenetic regulation of regeneration has recently emerged as a possible 
pathway to hair cell replacement [54]. The improved FA found at Heschl’s gyrus 
may represent a rescue of the auditory cortex from sound deprived visual fate back 
to its original hearing function. That recovery appears to depend upon repair of the 
cochlea, the spiral ganglion, the eighth cranial nerve, and the white matter tracts 
of the auditory pathways. All of these repairs may be facilitated by intravenous 
mesenchymal stem cell treatment [55].
2. Conclusion(s)
SNHL is a permanent sensory disorder and a significant worldwide public health 
problem. Untreated sound deprivation causes permanent reorganization of the 
auditory pathways that first interferes with and then prevents the development of 
spoken language. Current treatments augment the function of a damaged cochlea 
and no reparative treatments currently exist. Both preclinical and clinical data sug-
gest that treatment with progenitor cells may result in cochlear repair in mammals. 
In addition, very limited data suggest that the repair process may extend beyond the 
cochlea to the auditory pathways and auditory cortex. This evolving area of research 
may allow the development of a reparative treatment for non-genetic SNHL.
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